[{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seaver Autism Center for Research and Treatment","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seaver Autism Center for Research and Treatment","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seaver Autism Center for Research and Treatment \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seaver Autism Center for Research and Treatment \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Stevanato Group","sponsor":"Bexson Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Stevanato Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Stevanato Group \/ Bexson Biomedical","highestDevelopmentStatusID":"1","companyTruncated":"Stevanato Group \/ Bexson Biomedical"},{"orgOrder":0,"company":"Irvine School of Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Irvine School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Irvine School of Medicine \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Irvine School of Medicine \/ Not Applicable"},{"orgOrder":0,"company":"ImprimisRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Approved","graph3":"ImprimisRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Troche","sponsorNew":"ImprimisRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"ImprimisRx \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Lind Global Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2020","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Seelos Therapeutics \/ Lind Global Asset Management","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Lind Global Asset Management"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Noetic Psychedelic Fund","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Bexson Biomedical \/ Noetic Psychedelic Fund","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Biomedical \/ Noetic Psychedelic Fund"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal spray","sponsorNew":"Vyera Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Vyera Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"University of Kansas","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"iGluRs","graph1":"Neurology","graph2":"Preclinical","graph3":"University of Kansas","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"University of Kansas \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"University of Kansas \/ PharmaTher"},{"orgOrder":0,"company":"Zylo Therapeutics","sponsor":"Silo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","graph1":"Neurology","graph2":"Undisclosed","graph3":"Zylo Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sustained Transdermal","sponsorNew":"Zylo Therapeutics \/ Silo Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Zylo Therapeutics \/ Silo Pharma"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bexson Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"TSRL","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ TSRL","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ TSRL"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Government of Canada","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Ketamine Hydrochloride","moa":"iGluRs","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Government of Canada","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Government of Canada"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intranasal Spray","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"The University of Kansas","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ The University of Kansas","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ The University of Kansas"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Prolonged-release","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Harrow Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase I","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Harrow Health","highestDevelopmentStatusID":"6","companyTruncated":"Melt Pharmaceuticals \/ Harrow Health"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Delic Corp","sponsor":"Ketamine Wellness Centers","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Delic Corp","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Delic Corp \/ Ketamine Wellness Centers","highestDevelopmentStatusID":"1","companyTruncated":"Delic Corp \/ Ketamine Wellness Centers"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Silo Pharma \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Columbia University"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Alcami","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Alcami Corporation","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher \/ Alcami Corporation"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"iX Biopharma","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"iX Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Wafer","sponsorNew":"iX Biopharma \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"iX Biopharma \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"EF Hutton","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Pasithea Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Pasithea Therapeutics \/ EF Hutton","highestDevelopmentStatusID":"1","companyTruncated":"Pasithea Therapeutics \/ EF Hutton"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","graph1":"Neurology","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA 3A","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"LTS - Lohmann Therapie Systeme","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"LTS - Lohmann Therapie Systeme","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"LTS - Lohmann Therapie Systeme \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"LTS - Lohmann Therapie Systeme \/ PharmaTher"},{"orgOrder":0,"company":"MD Infusions","sponsor":"Front Door Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"MD Infusions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MD Infusions \/ Front Door Health","highestDevelopmentStatusID":"1","companyTruncated":"MD Infusions \/ Front Door Health"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Braxia Scientific \/ Not Applicable"},{"orgOrder":0,"company":"Revitalist Lifestyle and Wellness","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Revitalist Lifestyle and Wellness","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Revitalist Lifestyle and Wellness \/ PharmaTher","highestDevelopmentStatusID":"4","companyTruncated":"Revitalist Lifestyle and Wellness \/ PharmaTher"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Braxia Scientific \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Braxia Scientific \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Gesval S.A.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Gesval S.A.","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Gesval S.A."},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"GABA A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Melt Pharmaceuticals \/ Catalent","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Catalent"},{"orgOrder":0,"company":"PharmaTher","sponsor":"CC Biotechnology Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"PharmaTher \/ CC Biotechnology Corporation","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ CC Biotechnology Corporation"},{"orgOrder":0,"company":"Bexson Biomedical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Bexson Biomedical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous injection","sponsorNew":"Bexson Biomedical \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bexson Biomedical \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"HMNC Brain Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"LTS LOHMANN Therapie-Systeme AG","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG","highestDevelopmentStatusID":"5","companyTruncated":"PharmaTher \/ LTS LOHMANN Therapie-Systeme AG"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Acadia Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Case Western Reserve University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Case Western Reserve University","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Case Western Reserve University"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"GABA A receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Harrow","sponsor":"iOR Partners","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Harrow","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Harrow \/ iOR Partners","highestDevelopmentStatusID":"12","companyTruncated":"Harrow \/ iOR Partners"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Psycheceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"iNGEN\u016b","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Psycheceutical \/ iNGEN\u016b","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ iNGEN\u016b"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Midomafetamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clearmind Medicine \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Not Applicable"},{"orgOrder":0,"company":"ERP Biomarker Qualification Consortium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"ERP Biomarker Qualification Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"ERP Biomarker Qualification Consortium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ERP Biomarker Qualification Consortium \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Psycheceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Psycheceutical","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Psycheceutical \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Psycheceutical \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Develco Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Develco Pharma \/ HMNC Brain Health","highestDevelopmentStatusID":"8","companyTruncated":"Develco Pharma \/ HMNC Brain Health"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Neurocentrx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Silo Pharma \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Vitruvias Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Vitruvias Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Vitruvias Therapeutics"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Zylo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Implant","sponsorNew":"Silo Pharma \/ Zylo Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Silo Pharma \/ Zylo Therapeutics"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"LongeVC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Freedom Biosciences \/ LongeVC","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ LongeVC"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Not Applicable"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Prolonged-release Formulation","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Melt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Melt Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Melt Pharmaceuticals"},{"orgOrder":0,"company":"Undisclosed","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Undisclosed \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Undisclosed \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Nephron Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Nephron Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Neurocentrx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Neurocentrx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Immediate Release Capsule","sponsorNew":"Neurocentrx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocentrx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ketabon","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ketabon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Prolonged-release Formulation","sponsorNew":"Ketabon \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ketabon \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"HOPE Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"HOPE Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"HOPE Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"HOPE Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Madrigal Mental Care","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Madrigal Mental Care","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Madrigal Mental Care \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Madrigal Mental Care \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Newbridge Securities Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Series B Financing","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Melt Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Melt Pharmaceuticals \/ Newbridge Securities Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Melt Pharmaceuticals \/ Newbridge Securities Corporation"},{"orgOrder":0,"company":"Mira Pharmaceuticals","sponsor":"Frontage Laboratories, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Mira Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Mira Pharmaceuticals \/ Frontage Laboratories, Inc"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Seelos Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"NRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"PharmaTher \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"PharmaTher \/ Not Applicable"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Anson Funds","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"NRx Pharmaceuticals \/ Anson Funds","highestDevelopmentStatusID":"14","companyTruncated":"NRx Pharmaceuticals \/ Anson Funds"},{"orgOrder":0,"company":"Silo Pharma","sponsor":"Sever Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Silo Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Silo Pharma \/ Sever Pharma Solutions","highestDevelopmentStatusID":"14","companyTruncated":"Silo Pharma \/ Sever Pharma Solutions"},{"orgOrder":0,"company":"Cessatech","sponsor":"Proveca","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Cessatech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Cessatech \/ Proveca","highestDevelopmentStatusID":"14","companyTruncated":"Cessatech \/ Proveca"},{"orgOrder":0,"company":"Awakn Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Awakn Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Awakn Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Awakn Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Melt Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Midazolam","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Melt Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Melt Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Melt Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ketamine Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Douglas CDMO \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Douglas CDMO \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Douglas CDMO develops, manufactures, and packs various dosage forms, and provides regulatory support for international distribution.
